NASDAQ:VECT VectivBio (VECT) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free VECT Stock Alerts $16.85 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$16.85▼$16.8550-Day Range$16.85▼$16.8552-Week Range$4.25▼$16.98VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get VectivBio alerts: Email Address Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About VectivBio Stock (NASDAQ:VECT)VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.Read More VECT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VECT Stock News HeadlinesApril 5, 2024 | uk.finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthMarch 18, 2024 | msn.comPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 1, 2024 | msn.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyFebruary 29, 2024 | reuters.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | benzinga.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | ft.comOnly two sleeps left until February 31!February 22, 2024 | finance.yahoo.comShort Bowel Syndrome Market Size and Share is Anticipated to Surge During the Study Period (2020–2034) | DelveInsightApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 16, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call TranscriptDecember 13, 2023 | msn.comIronwood seals the deal on VectivBio mergerDecember 12, 2023 | finance.yahoo.comIronwood Announces the Completion of Squeeze-Out Merger With VectivBioNovember 15, 2023 | tmcnet.comReverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous CytokinesNovember 10, 2023 | msn.comIronwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesNovember 10, 2023 | markets.businessinsider.comAkash Tewari’s Buy Rating on Ironwood Pharma: Linzess Floor Trading and Apraglutide’s Promising FutureNovember 10, 2023 | markets.businessinsider.comHold Rating for Ironwood Pharma Driven by Stable Linzess Revenue and Anticipated Apraglutide Data, Despite T Cell Data DelayNovember 9, 2023 | finance.yahoo.comIronwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year GuidanceOctober 27, 2023 | msn.comIronwood Pharmaceuticals: The Right Play NowOctober 16, 2023 | markets.businessinsider.comIronwood Pharmaceuticals’ Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler’s Buy RatingSeptember 7, 2023 | finance.yahoo.comWhy Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?August 23, 2023 | markets.businessinsider.comEQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 23, 2023 | finance.yahoo.comAbivax Appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 9, 2023 | msn.comIronwood's (IRWD) Reports Q2 Loss, Linzess Volume RisesAugust 9, 2023 | uk.finance.yahoo.comQ2 2023 Ironwood Pharmaceuticals Inc Earnings CallJuly 16, 2023 | theglobeandmail.comInstrument Name Vectivbio Holding Ag Instrument Symbol (VECT-Q)June 29, 2023 | finance.yahoo.comIronwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesJune 27, 2023 | finanznachrichten.deVectivBio AG: VectivBio Extraordinary General Meeting of Shareholders Approved All ProposalsSee More Headlines Receive VECT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VECT CUSIPN/A CIK1836379 Webvectivbio.com Phone41-61-551-3030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$27.34 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book2.69Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Luca Santarelli M.D. (Age 53)Founder, CEO & Director Ms. Claudia D'Augusta Ph.D. (Age 53)Chief Financial Officer Dr. Christian Meyer M.D. (Age 56)Ph.D., Chief Operating Officer Dr. Alain Bernard Ph.D. (Age 66)Chief Technology Officer Mr. Patrick MalloySr. VP of Investor Relations & Strategic CommunicationsMr. Scott Applebaum (Age 56)Chief Legal Officer & Corp. Sec. Mr. Michael SteiningerSr. VP & Head of HRMr. Kevin Harris M.B.A. (Age 52)Chief Commercial Officer Dr. Sarah Holland Ph.D. (Age 60)Chief Bus. Officer Dr. Omar Khwaja M.D. (Age 53)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsAlvotechNYSE:ALVOGenocea BiosciencesNASDAQ:GNCAQ180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWView All Competitors VECT Stock Analysis - Frequently Asked Questions Should I buy or sell VectivBio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VECT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VECT, but not buy additional shares or sell existing shares. View VECT analyst ratings or view top-rated stocks. How have VECT shares performed in 2024? VectivBio's stock was trading at $16.85 at the beginning of the year. Since then, VECT shares have increased by 0.0% and is now trading at $16.85. View the best growth stocks for 2024 here. When did VectivBio IPO? VectivBio (VECT) raised $128 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 7,500,000 shares at a price of $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of VectivBio? Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VECT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
